Dupixent's status as a pipeline in a product has been further cemented by positive data in patients with prurigo nodularis, the sixth disease that Sanofi's blockbuster has succeeded in at Phase III.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?